The new chairman of the Biotechnology Innovation Organization (BIO) is promising to crack down on “bad actors” that increase drug prices “dramatically”—in part by expelling member companies that carry out the sky-high hikes.
Jeremy M. Levin, D.Phil., MB BChir., who is also chairman and CEO of Ovid Therapeutics, told GEN such expulsions would be considered individually, and didn’t define how high a dramatic price increase would be to incur the wrath of BIO.
Image: Jeremy Levin, D.Phil., MB BChir., new Chairman of the Biotechnology Innovation Organization. (Alex Philippidis)
